6533b836fe1ef96bd12a0bb1

RESEARCH PRODUCT

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.

Rui Ru JiYumei YangYajin QuUgur SahinChuan QinAnnette B. VogelHua ZhuAimin Hui

subject

0301 basic medicineGenetically modified mouseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)TransgenevirusesImmunologyefficacylcsh:Medicineimmunogenicitychallenge study03 medical and health sciences0302 clinical medicineDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicinePharmacologyMessenger RNAbiologybusiness.industrySARS-CoV-2Brief ReportImmunogenicitylcsh:RCOVID-19VirologyTiter030104 developmental biologyInfectious DiseasesmRNA vaccineImmunizationbiology.proteinAntibodybusiness

description

BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2, which correlated with viral clearance and alleviated lung lesions in these mice after viral challenge.

yearjournalcountryeditionlanguage
2021-04-01Vaccines
10.3390/vaccines9040324https://pubmed.ncbi.nlm.nih.gov/33915773